Skip to main content

Injectable vs Oral Semaglutide Dosing

Last updated: June 2026

Injectable and oral semaglutide are the same molecule, but their dose numbers do not line up: the injectable (Ozempic, Wegovy) is dosed in milligrams once a week, while the oral tablet (Rybelsus) is dosed in milligrams once a day on a completely different scale. The reason is bioavailability — only a tiny fraction of a swallowed tablet reaches the blood, so 14 mg by mouth daily is roughly comparable to about 0.5 mg injected weekly, not to 14 mg of anything injected.

Got an injectable vial and a target weekly dose? Convert it to exact mL and U-100 syringe units in seconds.

Semaglutide calculator →

TL;DR — key takeaways

  • Same drug, two number lines. Injectable semaglutide steps 0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly; oral Rybelsus steps 3 → 7 → 14 mg daily.
  • Bioavailability is why. Oral semaglutide is absorbed at roughly 1% of the swallowed dose, so the milligram numbers are not interchangeable across routes.
  • The unit maths only applies to the injectable. Tablets are swallowed whole — there are no syringe units. For a vial, units follow concentration (mg/mL), not the drug name.
  • Never convert routes yourself. Switching between Rybelsus and an injectable is a prescriber decision with its own starting dose and titration.

Why the two dose scales look so different

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — one molecule, whether it arrives by injection or by mouth. The difference is how it gets into the bloodstream. Injected under the skin, almost the entire dose is absorbed. Swallowed as a tablet, semaglutide is a large peptide that the stomach would normally destroy, so Rybelsus co-formulates it with an absorption enhancer (salcaprozate sodium, or SNAC) that creates a small local window for uptake. Even with SNAC, only on the order of 1% of the oral dose reaches the circulation, and absorption is highly variable between people and sensitive to food and water timing.

That single fact — about 1% oral bioavailability — is why the numbers cannot be compared milligram-for-milligram. A 14 mg tablet is the maximum approved Rybelsus dose, yet pharmacologically it lands near the lower-to-middle end of the injectable range. So a bigger oral number does not mean a bigger effective dose than a smaller injectable one.

Frequency differs for the same reason chained to half-life. Semaglutide has an elimination half-life of about one week, which is what allows the injectable to be dosed weekly and still hold a steady level. The oral tablet is taken daily because each day's absorption is small and erratic; daily dosing smooths that out and keeps the blood level topped up.

Side-by-side: the two formulations

PropertyInjectable (Ozempic / Wegovy)Oral (Rybelsus)
RouteSubcutaneous injectionTablet, swallowed whole
ScheduleOnce weeklyOnce daily, on an empty stomach
Dose steps0.25, 0.5, 1, 1.7, 2.4 mg/week3, 7, 14 mg/day
Approx. bioavailability~89% (subcutaneous)~1% (with SNAC enhancer)
Min step interval4 weeks30 days (3→7), then 30 days (7→14)
Half-life~1 week~1 week
Syringe units?Yes — depends on vial mg/mLNo — nothing to draw up

Figures reflect the FDA-approved Ozempic, Wegovy and Rybelsus labels. The 3 mg Rybelsus tablet is a starter dose for tolerability only and is not considered effective for glucose control on its own — it exists to bridge to 7 mg. Compounded injectable vials are drawn manually and require you to calculate the draw volume yourself; prescribed protocols may differ, so follow your prescriber's instructions.

Approximate dose alignment, visualised

The two scales are not a clean conversion, but the diagram below shows roughly where each oral daily dose sits against the injectable weekly ladder. Treat it as orientation, not a conversion you can act on.

Oral (daily mg) Injectable (weekly mg) 3 mg 7 mg 14 mg 0.25 mg 0.5 mg 1 mg 7 mg/day ≈ ~0.5 mg/week 14 mg/day ≈ ~0.5–1 mg/week Approximate only — not a conversion factor

The unit maths — injectable only

Here is the part that trips people up: a tablet has no syringe units, but an injectable vial does, and the milligram dose on the label is not what you read on the syringe. You read units, and a U-100 insulin syringe has 100 units per 1 mL. The conversion is always the same: find the concentration (mg/mL), divide your weekly dose by it to get mL, then multiply by 100 to get units.

Worked example 1 — injectable starter dose

You have a vial labelled 2.5 mg/mL and your prescribed dose is 0.25 mg/week.

0.25 mg ÷ 2.5 mg/mL = 0.1 mL.   0.1 mL × 100 units/mL = 10 units.

Draw 10 units on a U-100 syringe.

Worked example 2 — a higher weekly dose

Same 2.5 mg/mL vial, but your dose has stepped up to 1 mg/week.

1 mg ÷ 2.5 mg/mL = 0.4 mL.   0.4 mL × 100 units/mL = 40 units.

Draw 40 units — four times the starter draw, because the dose is four times larger.

Worked example 3 — same dose, stronger vial

The same 1 mg dose from a 5 mg/mL vial: 1 ÷ 5 = 0.2 mL × 100 = 20 units.

Double the concentration, half the units — for the identical milligram dose. This is why "how many units" has no single answer without the vial strength. (None of this applies to Rybelsus, which is swallowed whole.)

Injectable dose-to-units reference chart

Common weekly injectable doses, shown as units on a U-100 syringe at two typical compounded concentrations. Always confirm against your own vial label. Oral Rybelsus is omitted on purpose — there is nothing to draw.

Weekly doseAt 2.5 mg/mLAt 5 mg/mL
0.25 mg (start)10 units5 units
0.5 mg20 units10 units
1 mg40 units20 units
1.7 mg68 units34 units
2.4 mg (max)96 units48 units

Notice the 2.4 mg row at 2.5 mg/mL needs 96 units — nearly a full 1 mL syringe. If a draw approaches or exceeds 1 mL, ask your pharmacy about a higher-concentration vial so the volume stays comfortable.

How this is calculated

Every injectable figure here uses two facts only: a U-100 syringe holds 100 units per mL, and concentration is dose-per-volume (units = dose ÷ mg/mL × 100). There is no route-specific or drug-specific magic constant in that arithmetic. What route does change is the dose your prescriber sets — because oral and injectable milligrams reflect totally different bioavailability — not the unit maths once a weekly injectable dose has been chosen. The calculators on this site automate exactly this and let you sanity-check the result against the chart above. None of this is medical advice; it is the maths behind a dose your prescriber has set.

Frequently asked questions

Is 14 mg Rybelsus the same as 14 mg injected?

No. Because oral semaglutide is absorbed at roughly 1% of the swallowed dose, 14 mg by mouth daily lands pharmacologically near the lower-to-middle of the injectable weekly range — not anywhere near 14 mg injected. The milligram numbers are not interchangeable across routes.

Why is the tablet daily but the injection weekly?

Semaglutide has an elimination half-life of about a week, so the injectable holds a steady level on weekly dosing. Oral absorption is small and variable each day, so daily dosing is used to keep the blood level topped up.

How many syringe units is a Rybelsus dose?

None — Rybelsus is a tablet swallowed whole, so there is nothing to draw up. Syringe units only apply to the injectable, and they depend on the vial concentration, not the drug name.

Can I switch from Rybelsus to the injectable myself by matching the mg?

No. Switching routes is a prescriber decision with its own starting dose and titration plan. Do not map an oral milligram number onto an injectable dose — the scales do not line up.

Sources

  1. RYBELSUS (semaglutide) tablets, for oral use — Prescribing Information (DailyMed / FDA label)
  2. OZEMPIC (semaglutide) injection, for subcutaneous use — Prescribing Information (DailyMed / FDA label)
  3. WEGOVY (semaglutide) injection, for subcutaneous use — Prescribing Information (DailyMed / FDA label)
  4. Aroda VR, et al. PIONEER 1: Efficacy and Safety of Oral Semaglutide Monotherapy vs Placebo in Type 2 Diabetes (Diabetes Care 2019)
  5. Pratley R, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4) (Lancet 2019)
  6. Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6) (N Engl J Med 2019)
  7. Hauge C, et al. The pharmacokinetics and comparative bioavailability of oral and subcutaneous semaglutide in healthy volunteers (J Basic Clin Physiol Pharmacol 2025)
  8. Anderson SL, et al. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care (Am J Manag Care 2020)
  9. PIONEER 1: Oral Semaglutide Monotherapy in Type 2 Diabetes, NCT02906930 (ClinicalTrials.gov)
  10. Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis (Cureus 2025)
  11. Clinical development of oral semaglutide for the treatment of type 2 diabetes: focusing on early-phase clinical trials and pharmacokinetics (Transl Clin Pharmacol 2025)
  12. Singh G, Krauthamer M, Bjalme-Evans M. Semaglutide (StatPearls, NCBI Bookshelf)

This guide is for general educational purposes only and does not constitute medical advice. Always follow your prescriber’s specific instructions and consult a qualified clinician before changing any protocol.

Suggest